5月7日,云顶新耀的布地奈德肠溶胶囊(耐赋康®)正式获得中国国家药品监督管理局(NMPA)的完全批准,这标志着该药物从附条件批准转为全面获批,也意味着其在IgA肾病治疗领域的地位进一步巩固,它成为国内首个且唯一获得完全批准的IgA肾病对因治疗药物,同时取消了对蛋白尿水平的限制,扩大了适用患者群体。布地奈德肠溶胶囊的完全批准基于全球III期临床试验NefIgArd研究的完整数据。这项研究覆盖了接受...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.